Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTEST Trial: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time
2024-517383-28-00Phase 3Authorised
- Sponsor
- University of Cincinnati College of Medicine
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) and brain hemorrhage (ICH) comparing NovoSeven (rFVIIa) with Placebo (2 arms). Planned start Jun 2022; status: authorised.
02
Drugs
coagulation factor VIIa
03
Conditions
intracerebral hemorrhage (ICH)brain hemorrhage (ICH)
Beyond the preview
Go deeper on 2024-517383-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517383-28-00.